|Optimizing the start time of statin therapy for patients with diabetes|
BT Denton, M Kurt, ND Shah, SC Bryant, SA Smith
Medical Decision Making 29 (3), 351-367, 2009
|Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence|
JE Mason, DA England, BT Denton, SA Smith, M Kurt, ND Shah
Medical Decision Making 32 (1), 154-166, 2012
|Optimally maintaining a Markovian deteriorating system with limited imperfect repairs|
M Kurt, JP Kharoufeh
European Journal of Operational Research 205 (2), 368-380, 2010
|The structure of optimal statin initiation policies for patients with type 2 diabetes|
M Kurt, BT Denton, AJ Schaefer, ND Shah, SA Smith
IIE Transactions on Healthcare Systems Engineering 1 (1), 49-65, 2011
|Monotone optimal replacement policies for a Markovian deteriorating system in a controllable environment|
M Kurt, JP Kharoufeh
Operations Research Letters 38 (4), 273-279, 2010
|From data to improved decisions: operations research in healthcare delivery|
M Capan, A Khojandi, BT Denton, KD Williams, T Ayer, J Chhatwal, ...
Medical Decision Making 37 (8), 849-859, 2017
|Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patients|
ND Shah, J Mason, M Kurt, BT Denton, AJ Schaefer, VM Montori, ...
PloS one 6 (1), e16170, 2011
|Structured replacement policies for a Markov-modulated shock model|
M Kurt, LM Maillart
Operations Research Letters 37 (4), 280-284, 2009
|What did time tell us? A comparison and retrospective validation of different survival extrapolation methods for immuno-oncologic therapy in advanced or metastatic renal cell …|
SL Klijn, E Fenwick, S Kroep, K Johannesen, B Malcolm, M Kurt, C Kiff, ...
PharmacoEconomics 39 (3), 345-356, 2021
|Dynamic decision models for managing the major complications of diabetes|
University of Pittsburgh, 2012
|Valuing prearranged paired kidney exchanges: A stochastic game approach|
M Kurt, MS Roberts, AJ Schaefer, MU Unver
Boston College Working Papers in Economics, 2011
|PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS|
S Kroep, C Kiff, C Kraan, M Bianco, K Johannesen, M Kurt, B Malcolm, ...
Value in Health 22, S523-S524, 2019
|Optimizing over Pure Stationary Equilibria in Consensus Stopping Games|
A Dehghanian, M Kurt, AJ Schaefer
forthcoming at Mathematical Programming Computation, 2018
|Comparative effectiveness of up to three lines of chemotherapy treatment plans for metastatic colorectal cancer|
I Toumazis, M Kurt, A Toumazi, LG Karacosta, C Kwon
MDM policy & practice 2 (2), 2381468317729650, 2017
|Chance-constrained programming models and approximations for general stochastic bottleneck spanning tree problems|
S Shen, M Kurt, J Wang
INFORMS Journal on Computing 27 (2), 301-316, 2015
|At what lipid ratios should a patient with type 2 diabetes initiate statins|
M Kurt, B Denton, AJ Schaefer, N Shah, S Smith
IIE Transactions on Healthcare Engineering 1 (1), 49-65, 2009
|Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial|
JS Weber, ...
ESMO 2019, 2019
|Lipid Ratio-Based Statin Initiation for Patients with Type 2 Diabetes|
M Kurt, BT Denton, AJ Schaefer, ND Shah, S Smith
|Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma|
V Federico Paly, M Kurt, L Zhang, MO Butler, O Michielin, A Amadi, ...
MDM policy & practice 7 (1), 23814683221089659, 2022
|Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.|
BA McGregor, S Petersohn, S Klijn, J May, F Ejzykowicz, M Kurt, M Dyer, ...
Journal of Clinical Oncology 40 (6_suppl), 391-391, 2022